# A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadine

> **NCT07465731** · PHASE1 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 62 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Centanafadine SR
- **DRUG:** Centanafadine QD XR

## Key facts

- **NCT ID:** NCT07465731
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-27
- **Primary completion:** 2023-03-26
- **Final completion:** 2023-03-26
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07465731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07465731, "A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07465731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*